Anti-Digoxin Fab Variants Generated by Phage Display
详细信息 查看全文
- 作者：Viviane Midori Murata (1)
Mariana Costa Braga Schmidt (1)
Jorge Kalil (2) (3)
Lilian Rumi Tsuruta (1)
Ana Maria Moro (1) (3) - 关键词：Digoxin ; Phage display ; CDR ; Framework ; Biacore ; Affinity ; Cardiac dysfunction
- 刊名：Molecular Biotechnology
- 出版年：2013
- 出版时间：June 2013
- 年：2013
- 卷：54
- 期：2
- 页码：269-277
- 全文大小：263KB
- 参考文献：1. Adams, K. F, Jr, Fonarow, G. C., Emermam, C. L., LeJemtel, T. H., Constanzo, M. R., Abraham, W. T., et al. (2005). Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminar observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). / American Heart Journal, / 149, 209-16. CrossRef
2. Gheorghiade, M., van Veldhuisen, D. J., & Colucci, W. S. (2006). Contemporary use of digoxin in the management of cardiovascular disorders. / Circulation, / 113, 2556-564. CrossRef
3. Andrés, V. L. G. (2000). Revisión sistemática sobre la efectividad e indicaciones de los anticuerpos antidigoxina en la intoxicación digitálica. / Revista Espanola de Cardiologia, / 53, 49-8. CrossRef
4. Antman, E. M., & Smith, T. W. (1985). Digitalis toxicity. / Annual Review of Medicine, / 36, 357-67. CrossRef
5. Butler, V. P, Jr, & Chen, J. P. (1967). Digoxin-specific antibodies. / Proceedings of the National Academy of Sciences of the United States of America, / 57, 71-8. CrossRef
6. Smith, T. W., Haber, E., Yetman, L., & Butler,. Jr. (1976). Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. / The New England Journal of Medicine, / 294, 797-00. CrossRef
7. Butler, V. P, Jr, Schmidt, D. H., Smith, T. W., Haber, E., Raynor, B. D., & Demartini, P. (1977). Effects of sheep digoxin-specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs. / The Journal of Clinical Investigation, / 59, 345-59. CrossRef
8. Lapostolle, F., Borron, S. W., Verdier, C., Taboulet, P., Guerrier, G., Adnet, F., et al. (2008). Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. / Critical Care Medicine, / 36, 3014-018. CrossRef
9. Eichhorn, E. J., & Gheorghiade, M. (2002). Digoxin. / Progress in Cardiovascular Diseases, / 44, 251-66. CrossRef
10. Flanagan, R. J., & Jones, A. L. (2004). Fab antibody fragments: some applications in clinical toxicology. / Drug Safety, / 27, 1115-133. CrossRef
11. Kwong, K. Y. & Rader, C. (2009). / E. coli expression and purification of Fab antibody fragments, in Current Protocols in Protein Science, vol. 55 Chapter 6: Purification of Recombinant Proteins (Wiley) pp. 6.10.1, 6.10.14.
12. Smith, G. P. (1985). Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. / Science, / 228, 1315-317. CrossRef
13. Orlandi, R., Güssow, D. H., Jones, P. T., & Winter, G. (1989). Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. / Proceedings of the National Academy of Sciences of the United States of America, / 86, 3833-837. CrossRef
14. McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990). Phage antibodies: Filamentous phage displaying antibody variable domains. / Nature, / 348, 552-54. CrossRef
15. Barbas, C. F, 3rd, Kang, A. S., Lerner, R. A., & Benkovic, S. J. (1991). Assembly of combinatorial antibody libraries on phage surfaces: The gene III site. / Proceedings of the National Academy of Sciences of the United States of America, / 88, 7978-982. CrossRef
16. Clackson, T., Hoogenboom, H. R., Griffiths, A. D., & Winter, G. (1991). Making antibody fragments using phage display libraries. / Nature, / 352, 624-28. CrossRef
17. Paula De, F. J. (1993) Fra??o sérica de pacientes urêmicos expandidos com atividade digoxina-símile inibidora da Na+K+ATPase: Isolamento, efeitos biológicos e caracteriza??o com anticorpos monoclonais, Ph.D. thesis, University of S?o Paulo, S?o Paulo, BR.
18. Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S., & Foeller, C. (1991). / Sequences of proteins of immunological interest. Bethesda, MD: US Department of Health and Human Services, Public Health Sciences, National Institute of Health.
19. Barbas, C. F., Burton, D. R., Scott, J. K., & Silverman, G. J. (2001). / Phage display: A laboratory manual. New York: Cold Spring Harbor Laboratory Press.
20. Tsuruta, L. R., Tomioka, Y., Hishinuma, T., Kato, Y., Itoh, K., Suzuki, T., et al. (2003). Characterization of 11-dehydro-thromboxane B2 recombinant antibody obtained by phage display technology. / Prostaglandins Leukotrienes and Essential Fatty Acids, / 68, 273-84. CrossRef
21. Erlanger, B. F., & Beiser, S. M. (1964). Antibodies specific for ribonucleosides and ribonucleotides and their reaction with DNA. / Proceedings of the National Academy of Sciences of the United States of America, / 52, 68-4. CrossRef
22. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990). Basic local alignment search tool. / Journal of Molecular Biology, / 215, 403-10.
23. Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., et al. (2007). ClustalW and ClustalX version 2.0. / Bioinformatics, / 23, 2947-948. CrossRef
24. Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. (1991). By-passing immunization. Human antibodies from V-gene libraries displayed on phage. / Journal of Molecular Biology, / 222, 581-97. CrossRef
25. Arap, M. A. (2005). Phage display technology—applications and innovations. / Genetics and Molecular Biology, / 28, 1-. CrossRef
26. Levy, R., Molineux, I. J., Iverson, B. L., & Georgiou, G. (2007). Isolation of trans-acting genes that enhance soluble expression of scFv antibodies in the E. coli cytoplasm by lambda phage display. / Journal of Immunological Methods, / 321, 164-73. CrossRef
27. Kuba, H., Furukawa, A., Okajima, T., & Furukawa, K. (2008). Efficient bacterial production of functional antibody fragments using a phagemid vector. / Protein Expression and Purification, / 58, 292-00. CrossRef
28. Schasfoort, R. B. M., & Tudos, A. J. (2008). / Handbook of surface plasmon resonance. Cambridge: Royal Society of Chemistry Publishing. CrossRef
29. Rinderknecht, M., Villa, A., Ballmer-Hofer, K., Neri, D., & Detmar, M. (2010). Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. / PLoS ONE, / 5, e11941. CrossRef
30. Hunter, M. M., Margolies, M. N., Ju, A., & Haber, E. (1982). High-affinity monoclonal antibodies to the cardiac glycoside, digoxin. / Journal of Immunology, / 129, 1165-172.
31. Mudgett-Hunter, M., Anderson, W., Haber, E., & Margolies, M. N. (1985). Binding and structural diversity among high-affinity monoclonal anti-digoxin antibodies. / Molecular Immunology, / 22, 477-88. CrossRef
32. Schildbach, J. F., Panka, D. J., Parks, D. R., Jager, G. C., Novotny, J., Herzenberg, L. A., et al. (1991). Altered hapten recognition by two anti-digoxin hybridoma variants due to variable region point mutations. / Journal of Biological Chemistry, / 266, 4640-647.
33. Schildbach, J. F., Near, R. I., Bruccoleri, R. E., Haber, E., Jeffrey, P. D., Ng, S. C., et al. (1993). Heavy chain position 50 is a determinant of affinity and specificity for the anti-digoxin antibody 26-10. / Journal of Biological Chemistry, / 268, 21739-1747.
34. Schildbach, J. F., Shaw, S. Y., Bruccoleri, R. E., Haber, E., Herzenberg, L. A., Jager, G. C., et al. (1994). Contribution of a single heavy chain residue to specificity of an anti-digoxin monoclonal antibody. / Protein Science, / 3, 737-49. CrossRef
35. Short, M. K., Jeffrey, P. D., Kwong, R. F., & Margolies, M. N. (1995). Contribution of antibody heavy chain CDR1 to digoxin binding analyzed by random mutagenesis of phage-displayed Fab 26-10. / Journal of Biological Chemistry, / 270, 28541-8550. CrossRef
36. Panka, D. J., Mudgett-Hunter, M., Parks, D. R., Peterson, L. L., Herzenberg, L. A., Haber, E., et al. (1988). Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. / Proceedings of the National Academy of Sciences of the United States of America, / 85, 3080-084. CrossRef
37. Caldas, C., Coelho, V., Kalil, J., Moro, A. M., Maranh?o, A. Q., & Brígido, M. M. (2003). Humanization of the anti-CD18 antibody 6.7: An unexpected effect of a framework residue in binding to antigen. / Molecular Immunology, / 39, 941-52. CrossRef
38. Horwitz, A. H., Nadell, R., Preugschat, F., & Better, M. (1994). Chimeric immunoglobulin light chains are secreted at different levels: Influence of framework-1 amino acids. / Molecular Immunology, / 31, 683-92. CrossRef
39. Bong, Y. S., Cho, S. H., Nham, S. U., & Lee, Y. I. (1998). Cloning and characterization of cDNAs coding for heavy and light chains of agglutinating monoclonal antibody (HAG12islrh) specific for human red blood cells. / Biochimica et Biophysica Acta, / 10, 156-58. CrossRef
40. Lai, Y. S., John, J. A., Guo, I. C., Chen, S. C., Fang, K., & Chang, C. Y. (2002). In vitro efficiency of intra- and extracellular immunization with mouse anti-YGNNV antibody against yellow grouper nervous necrosis virus. / Vaccine, / 20, 3221-229. CrossRef
41. Argiriadi, M. A., Xiang, T., Wu, C., Ghayur, T., & Borhani, D. W. (2009). Unusual water-mediated antigenic recognition of the proinflammatory cytokine interleukin-18. / Journal of Biological Chemistry, / 36, 24478-4489. CrossRef
42. Gon?alves, O., Dintinger, T., Lebreton, J., Blanchard, D., & Tellier, C. (2000). Mechanism of an antibody-catalysed allylic isomerization. / The Biochemical Journal, / 3, 691-98. CrossRef
43. Golinelli-Pimpaneau, B., Goncalves, O., Dintinger, T., Blanchard, D., Knossow, M., & Tellier, C. (2000). Structural evidence for a programmed general base in the active site of a catalytic antibody. / Proceedings of the National Academy of Sciences of the United States of America, / 18, 9892-895. CrossRef
44. Costagliola, S., Bonomi, M., Morgenthaler, N. G., Van Durme, J., Panneels, V., Refetoff, S., et al. (2004). Delineation of the discontinuous-conformational epitope of a monoclonal antibody displaying full in vitro and in vivo thyrotropin activity. / Molecular Endocrinology, / 18, 3020-034. CrossRef - 作者单位：Viviane Midori Murata (1)
Mariana Costa Braga Schmidt (1)
Jorge Kalil (2) (3)
Lilian Rumi Tsuruta (1)
Ana Maria Moro (1) (3)
1. Laboratorio de Biofarmacos em Celulas Animais, Instituto Butantan, S?o Paulo, SP, 05503-900, Brazil
2. Laboratorio de Imunologia, InCor, Universidade de Sao Paulo, S?o Paulo, SP, 05403-000, Brazil
3. Institute for Immunology Investigation–Science and Technology National Institutes, INCT, S?o Paulo, Brazil
文摘
Digoxin is a pharmaceutical used in the control of cardiac dysfunction. Its therapeutic window is narrow, with effect dosage very close to the toxic dosage. To counteract the toxic effect, polyclonal Fab fragments are commercially available. Our study is based on a monoclonal anti-digoxin antibody, which would provide a product with a specific potency and more precise dosage for the detoxification of patients under digoxin treatment. Phage display technology was used to select variants with high affinity. From an anti-digoxin hybridoma, RNA was extracted for subsequent cDNA synthesis. Specific primers were used for the LC and Fd amplifications, then cloned sequentially in a phagemid vector (pComb3X) for the combinatorial Fab library construction. Clones were selected for their ability to bind to digoxin-BSA. The presence of light and heavy chains was checked, randomly selected clones then sequenced and induced to produce soluble Fabs, and subsequently analyzed for anti-digoxin expression. Out of ten clones randomly chosen, six resulted positive expression of the product. The sequencing of these revealed two identical clones and one presenting a pseudogene in the LC. Four clones presenting variations in the framework1 showed binding to digoxin-BSA by ELISA and western blotting. The specific binding was further confirmed by Biacore?, which allowed ranking of the clones. The development of these clones allowed the selection of variants with higher affinity than the original version.